Pulse.

a daily field guide to health research that matters

◆ Console

‹ Tue · 27 Oct 2026
Standard addition

Izalontamab brengitecan for HR+/HER2- breast cancer in China (PANKU-Breast01): a randomised, phase 3 trial.

A new drug combination shows promise for treating hormone-receptor-positive breast cancer that has resisted prior treatments.

The aim of PANKU-Breast01 was to compare the efficacy and safety of iza-bren versus chemotherapy in patients with pretreated HR+/HER2- breast cancer. Baili-Bio (Chengdu) Pharmaceutical, CAMS Innovation Fund for Medical Sciences, Noncommunicable Chronic Diseases-National Science and Technology Major Project, National High Level Hospital Clinical Research Funding, and the National Natural Science Foundation of China.

What the study was

Study design
Randomized controlled trial
Category
Treatment Innovation
Maturity
Potentially Practice-Changing
Journal
Lancet

Why it surfaced

Randomized controlled trial; human evidence; PubMed abstract reviewed; conservative rubric score 10/10.

A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.